According to the American Diabetes Association (ADA) and European Association of Securities Dealers (ESAD) consensus report 2022, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are recommended as first-line therapy for people with combined atherosclerotic cardiovascular disease and the high-risk factors for cardiovascular disease (CVD) [2, 3]. This evidence concerns the gene GLP1R and diabetes mellitus.